TY - JOUR
T1 - Biomarker testing in lung carcinoma cytology specimens
T2 - A perspective from members of the Pulmonary Pathology Society
AU - Roy-Chowdhuri, Sinchita
AU - Aisner, Dara L.
AU - Allen, Timothy Craig
AU - Beasley, Mary Beth
AU - Borczuk, Alain
AU - Cagle, Philip T.
AU - Capelozzi, Vera
AU - Dacic, Sanja
AU - Da Cunha Santos, Gilda
AU - Hariri, Lida P.
AU - Kerr, Keith M.
AU - Lantuejoul, Sylvie
AU - Mino-Kenudson, Mari
AU - Moreira, Andre
AU - Raparia, Kirtee
AU - Rekhtman, Natasha
AU - Sholl, Lynette
AU - Thunnissen, Eric
AU - Tsao, Ming Sound
AU - Vivero, Marina
AU - Yatabe, Yasushi
N1 - Publisher Copyright:
© 2016, College of American Pathologists. All rights reserved.
PY - 2016/11
Y1 - 2016/11
N2 - The advent of targeted therapy in lung cancer has heralded a paradigm shift in the practice of cytopathology with the need for accurately subtyping lung carcinoma, as well as providing adequate material for molecular studies, to help guide clinical and therapeutic decisions. The variety and versatility of cytologic-specimen preparations offer significant advantages to molecular testing; however, they frequently remain underused. Therefore, evaluating the utility and adequacy of cytologic specimens is critical, not only from a lung cancer diagnosis standpoint but also for the myriad ancillary studies that are necessary to provide appropriate clinical management. A large fraction of lung cancers are diagnosed by aspiration or exfoliative cytology specimens, and thus, optimizing strategies to triage and best use the tissue for diagnosis and biomarker studies forms a critical component of lung cancer management. This review focuses on the opportunities and challenges of using cytologic specimens for molecular diagnosis of lung cancer and the role of cytopathology in the molecular era.
AB - The advent of targeted therapy in lung cancer has heralded a paradigm shift in the practice of cytopathology with the need for accurately subtyping lung carcinoma, as well as providing adequate material for molecular studies, to help guide clinical and therapeutic decisions. The variety and versatility of cytologic-specimen preparations offer significant advantages to molecular testing; however, they frequently remain underused. Therefore, evaluating the utility and adequacy of cytologic specimens is critical, not only from a lung cancer diagnosis standpoint but also for the myriad ancillary studies that are necessary to provide appropriate clinical management. A large fraction of lung cancers are diagnosed by aspiration or exfoliative cytology specimens, and thus, optimizing strategies to triage and best use the tissue for diagnosis and biomarker studies forms a critical component of lung cancer management. This review focuses on the opportunities and challenges of using cytologic specimens for molecular diagnosis of lung cancer and the role of cytopathology in the molecular era.
UR - http://www.scopus.com/inward/record.url?scp=84992672556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992672556&partnerID=8YFLogxK
U2 - 10.5858/arpa.2016-0091-SA
DO - 10.5858/arpa.2016-0091-SA
M3 - Review article
C2 - 27081878
AN - SCOPUS:84992672556
SN - 0003-9985
VL - 140
SP - 1267
EP - 1272
JO - Archives of Pathology and Laboratory Medicine
JF - Archives of Pathology and Laboratory Medicine
IS - 11
ER -